Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

• Published in: Science translational medicine Vol. 7; no. 319; p. 319ra206
• Main Authors: Lynch, Rebecca M, Boritz, Eli, Coates, Emily E, DeZure, Adam, Madden, Patrick, Costner, Pamela, Enama, Mary E, Plummer, Sarah, Holman, Lasonji, Hendel, Cynthia S, Gordon, Ingelise, Casazza, Joseph, Conan-Cibotti, Michelle, Migueles, Stephen A, Tressler, Randall, Bailer, Robert T, McDermott, Adrian, Narpala, Sandeep, O'Dell, Sijy, Wolf, Gideon, Lifson, Jeffrey D, Freemire, Brandie A, Gorelick, Robert J, Pandey, Janardan P, Mohan, Sarumathi, Chomont, Nicolas, Fromentin, Remi, Chun, Tae-Wook, Fauci, Anthony S, Schwartz, Richard M, Koup, Richard A, Douek, Daniel C, Hu, Zonghui, Capparelli, Edmund, Graham, Barney S, Mascola, John R, Ledgerwood, Julie E
• Format: Journal Article
• Language: English
• Published: United States 23.12.2015
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing - administration & dosage; Antibodies, Neutralizing - immunology; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes - immunology; Chronic Disease; HIV Antibodies - blood; HIV Infections - blood; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; HIV-1 - immunology; Humans; Kinetics; Middle Aged; Viral Load - immunology; Young Adult

Passive immunization with HIV-1-neutralizing monoclonal antibodies (mAbs) is being considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be used to suppress active virus replication, maintain suppression induced by antiretroviral therapy (ART), and/or decrease...